Main Menu

Making the discoveries that defeat cancer

The Institute of Cancer Research is one of the world’s most influential cancer research organisations. We are a UK charity and member institution of the University of London.

ICR announces appointment of new Chief Executive

Professor Kristian Helin, a world-leading cancer researcher with exceptional leadership experience in three different countries, will become Chief Executive of the ICR in September.
Read more
Ovarian cancer drug offers new genetically targeted approach against range of cancers

A type of drug used against ovarian and breast cancers could offer a brand new targeted approach for treating a range of cancers with particular genetic defects, including a common form of kidney cancer.
Read more
Our impact on ovarian cancer

Research carried out at the ICR has led to discoveries that greatly impact on ovarian cancer treatment, including better diagnostic and risk testing, the development of a new class of drugs and new targeted treatments.
Find out more

1/3

Making it count

We will deliver better outcomes and quality of life for patients by establishing innovative treatments, diagnostics and prevention strategies as part of routine healthcare.
Improving patient lives
Smarter, kinder treatments

We will move a step closer to cure by bringing personalised treatments into the clinic and developing them for patients.
Personalised treatments
Unravelling cancer’s complexity

We will comprehend the full complexity of cancer by harnessing the power of new technologies and Big Data.
Big data research
Queen's Anniversary Prize

The ICR has been recognised with a prestigious Queen’s Anniversary Prize for its world-leading research in cancer drug discovery.
Queen's Anniversary Prize
Innovative approaches

We will take on the challenge of cancer’s complexity, evolution and drug resistance through the discovery of innovative new approaches to cancer treatment.
Our innovative approaches
Creating new treatments that target tumours

Teams of biologists, chemists and computational scientists design new drugs to selectively attack tumours.
About drug discovery